Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices

Journal of Pharmaceutical Sciences

Volumn 105, Issue 11, 2016, Pages 3432-3439

  Bäckström, Erica ^a,b   Boger, Elin ^b,c   Lundqvist, Anders ^b   Hammarlund Udenaes, Margareta ^a   Fridén, Markus ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

distribution; pharmacokinetics; pulmonary; pulmonary drug delivery; tissue partition

Indexed keywords

AGAROSE; BRONCHODILATING AGENT; DIAZEPAM; FORMOTEROL; INDACATEROL; LACTATE DEHYDROGENASE; MONENSIN; SALBUTAMOL; SALMETEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RETENTION; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LIQUID CHROMATOGRAPHY; LUNG; LUNG SLICE; LYSOSOME; MALE; NONHUMAN; RAT; TANDEM MASS SPECTROMETRY; TIME; TURBIDITY; ANIMAL; DRUG EFFECTS; FORECASTING; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; ORGAN CULTURE TECHNIQUE; WISTAR RAT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BRONCHODILATOR AGENTS; FORECASTING; LUNG; LYSOSOMES; MALE; ORGAN CULTURE TECHNIQUES; RATS; RATS, WISTAR;

EID: 84991442171     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.08.014     Document Type: Article

References (28)

1. 1 Labiris, N.R., Dolovich, M.B., Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56 (2003), 588–599.
2. 2 Labiris, N.R., Dolovich, M.B., Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56 (2003), 600–612.
3. 3 Backman, P., Adelmann, H., Petersson, G., Jones, C.B., Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther 95 (2014), 509–520.
4. 4 Backstrom, E., Lundqvist, A., Boger, E., et al. Development of a novel lung slice methodology for profiling of inhaled compounds. J Pharm Sci 105 (2015), 838–845.
5. 5 Matsukawa, Y., Lee, V.H., Crandall, E.D., Kim, K.J., Size-dependent dextran transport across rat alveolar epithelial cell monolayers. J Pharm Sci 86 (1997), 305–309.
6. 6 Patton, J.S., Fishburn, C.S., Weers, J.G., The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1 (2004), 338–344.
7. 7 Boger, E., Ewing, P., Eriksson, U.G., et al. A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: toward an improved understanding of lung pharmacokinetic/pharmacodynamic relationships. J Pharmacol Exp Ther 353 (2015), 279–287.
8. 8 Cooper, A.E., Ferguson, D., Grime, K., Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab 13 (2012), 457–473.
9. 9 Boger, E., Evans, N., Chappell, M., et al. Systems pharmacology approach for prediction of pulmonary and systemic pharmacokinetics and receptor occupancy of inhaled drugs. CPT Pharmacometrics Syst Pharmacol 4 (2016), 201–210.
10. 10 Salomon, J.J., Hagos, Y., Petzke, S., et al. Beta-2 adrenergic agonists are substrates and inhibitors of human organic cation transporter 1. Mol Pharm 8 (2015), 2633–2641.
11. 11 Baur, F., Beattie, D., Beer, D., et al. The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. J Med Chem 53 (2010), 3675–3684.
12. 12 Cazzola, M., Testi, R., Matera, M.G., Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 41 (2002), 19–30.
13. 13 Yokogawa, K., Ishizaki, J., Ohkuma, S., Miyamoto, K., Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find Exp Clin Pharmacol 24 (2002), 81–93.
14. 14 Beeh, K.M., Beier, J., Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist. Core Evid 4 (2010), 37–41.
15. 15 Peters, S.A., Physiological model for distribution. Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry, 2012, Wiley, Hoboken, NJ.
16. 16 Upton, R.N., Doolette, D.J., Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol 26 (1999), 381–391.
17. 17 Stocks, M.J., Alcaraz, L., Bailey, A., et al. Discovery of AZD3199, an inhaled ultralong acting beta2 receptor agonist with rapid onset of action. ACS Med Chem Lett 5 (2014), 416–421.
18. 18 Siebert, G.A., Hung, D.Y., Chang, P., Roberts, M.S., Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther 308 (2004), 228–235.
19. 19 Aowicki, D., Huczynski, A., Structure and antimicrobial properties of monensin A and its derivatives: summary of the achievements. Biomed Res Int, 2013, 2013, 742149.
20. 20 Takasato, Y., Rapoport, S.I., Smith, Q.R., An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247 (1984), H484–H493.
21. 21 Waldeck, B., Beta-adrenoceptor agonists and asthma–100 years of development. Eur J Pharmacol 445 (2002), 1–12.
22. 22 Cazzola, M., Calzetta, L., Page, C.P., Matera, M.G., Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol 10 (2014), 129–137.
23. 23 Agarwal, S., Chinn, L., Zhang, L., An overview of transporter information in package inserts of recently approved new molecular entities. Pharm Res 30 (2013), 899–910.
24. 24 Cada, D.J., Ingram, K., Leonard, J., Baker, D.E., Umeclidinium bromide and vilanterol trifenatate inhalation powder. Hosp Pharm 49 (2014), 554–562.
25. 25 Nickel, S., Clerkin, C.G., Selo, M.A., Ehrhardt, C., Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opin Drug Deliv 13 (2016), 667–690.
26. 26 Friden, M., Bergstrom, F., Wan, H., et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39 (2011), 353–362.
27. 27 Borghardt, J.M., Weber, B., Staab, A., Kloft, C., Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J 17 (2015), 853–870.
28. 28 Borghardt, J.M., Weber, B., Staab, A., Kunz, C., Formella, S., Kloft, C., Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. Br J Clin Pharmacol 81 (2016), 538–552.